Thrombotic microangiopathy versus class IV lupus nephritis in systemic lupus erythematosus.
Lupus nephritis
Systemic lupus erythematosus
Thrombotic microangiopathy
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
10
11
2020
accepted:
19
02
2021
pubmed:
11
3
2021
medline:
29
1
2022
entrez:
10
3
2021
Statut:
ppublish
Résumé
Kidney involvement is common in patients with systemic lupus erythematosus (SLE). This study investigates the clinical and prognostic characteristics of thrombotic microangiopathy (TMA) compared to class IV lupus nephritis in SLE patients. A retrospective review of patients who underwent kidney biopsy, with a primary diagnosis of SLE and TMA between June 2006 and September 2018 was conducted. Those patients were subsequently compared to patients with class IV lupus nephritis between January 2018 and December 2018. Demographics, laboratory, and serological data at the time of biopsy were abstracted. Among 214 SLE patients records screened, 27 were included in the final analysis. Eight patients had lupus-related TMA without evidence of active lupus nephritis, while 19 patients had class IV lupus nephritis without evidence of TMA. TMA patients had significantly higher lactate dehydrogenase levels (718 ± 499 vs. 264 ± 107.7 U/L, p = 0.009), serum C3 (100.6 ± 39.3 vs. 65.8 ± 27 mg/dL, p = 0.049), white blood cell count (14743.8 ± 7933.3 vs. 5807.9 ± 2053.2 × 10E3/uL, p < 0.001), and total bilirubin (0.8 ± 0.5 vs. 0.3 ± 0.1 mg/dL, p = 0.007) in addition to significantly lower platelet counts (158.4 ± 88.6 vs. 240.3 ± 100.3 × 10E3/uL, p = 0.03), and haptoglobin (68.8 ± 116.1 vs. 166.8 ± 95.4 mg/dL, p = 0.03). After a median follow-up time of 53 weeks, 3 patients with TMA were dialysis-dependent (37.5%), compared with none in class IV lupus nephritis patients (p = 0.002). TMA-associated SLE has worse prognosis compared to class IV lupus nephritis. An array of laboratory and pathological findings may be of value in discriminating between those two entities.
Sections du résumé
BACKGROUND
BACKGROUND
Kidney involvement is common in patients with systemic lupus erythematosus (SLE). This study investigates the clinical and prognostic characteristics of thrombotic microangiopathy (TMA) compared to class IV lupus nephritis in SLE patients.
METHODS
METHODS
A retrospective review of patients who underwent kidney biopsy, with a primary diagnosis of SLE and TMA between June 2006 and September 2018 was conducted. Those patients were subsequently compared to patients with class IV lupus nephritis between January 2018 and December 2018. Demographics, laboratory, and serological data at the time of biopsy were abstracted.
RESULTS
RESULTS
Among 214 SLE patients records screened, 27 were included in the final analysis. Eight patients had lupus-related TMA without evidence of active lupus nephritis, while 19 patients had class IV lupus nephritis without evidence of TMA. TMA patients had significantly higher lactate dehydrogenase levels (718 ± 499 vs. 264 ± 107.7 U/L, p = 0.009), serum C3 (100.6 ± 39.3 vs. 65.8 ± 27 mg/dL, p = 0.049), white blood cell count (14743.8 ± 7933.3 vs. 5807.9 ± 2053.2 × 10E3/uL, p < 0.001), and total bilirubin (0.8 ± 0.5 vs. 0.3 ± 0.1 mg/dL, p = 0.007) in addition to significantly lower platelet counts (158.4 ± 88.6 vs. 240.3 ± 100.3 × 10E3/uL, p = 0.03), and haptoglobin (68.8 ± 116.1 vs. 166.8 ± 95.4 mg/dL, p = 0.03). After a median follow-up time of 53 weeks, 3 patients with TMA were dialysis-dependent (37.5%), compared with none in class IV lupus nephritis patients (p = 0.002).
CONCLUSIONS
CONCLUSIONS
TMA-associated SLE has worse prognosis compared to class IV lupus nephritis. An array of laboratory and pathological findings may be of value in discriminating between those two entities.
Identifiants
pubmed: 33689148
doi: 10.1007/s40620-021-01010-4
pii: 10.1007/s40620-021-01010-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1907-1913Informations de copyright
© 2021. Italian Society of Nephrology.
Références
Furst DE, Clarke AE, Fernandes AW, Bancroft T, Greth W, Iorga SR (2013) Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. Lupus 22(1):99–105
doi: 10.1177/0961203312463110
Yu F, Haas M, Glassock R, Zhao MH (2017) Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol 13(8):483–495
doi: 10.1038/nrneph.2017.85
Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M et al (2013) The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthr Res Ther 15(1):R12
doi: 10.1186/ar4142
Barrera-Vargas A, Rosado-Canto R, Merayo-Chalico J, Arreola-Guerra JM, Mejia-Vilet JM, Correa-Rotter R et al (2016) Renal thrombotic microangiopathy in proliferative lupus nephritis: risk factors and clinical outcomes: a case-control study. J Clin Rheumatol 22(5):235–240
doi: 10.1097/RHU.0000000000000425
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol JASN 15(2):241–250
doi: 10.1097/01.ASN.0000108969.21691.5D
Cameron JS (1999) Lupus nephritis. J Am Soc Nephrol JASN 10(2):413–424
doi: 10.1681/ASN.V102413
Imran TF, Yick F, Verma S, Estiverne C, Ogbonnaya-Odor C, Thiruvarudsothy S et al (2016) Lupus nephritis: an update. Clin Exp Nephrol 20(1):1–13
doi: 10.1007/s10157-015-1179-y
George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371(7):654–666
doi: 10.1056/NEJMra1312353
Bayer G, von Tokarski F (2019) Etiology outcomes of thrombotic microangiopathies. Clin J Am Soc Nephrol 14(4):557–566
doi: 10.2215/CJN.11470918
Hu W, Liu Z, Chen H, Zhang H, Li L, Liu Z (2010) Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus 19(14):1591–1598. https://doi.org/10.1177/0961203310376523
doi: 10.1177/0961203310376523
pubmed: 20798137
Li J, Jiang JJ, Wang CY, Jian S, Zhou Y, Ma MS et al (2019) Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases. Ital J Pediatr 45(1):55
doi: 10.1186/s13052-019-0641-y
Li C, Yap DYH, Chan G, Wen YB, Li H, Tang C et al (2019) Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy. J Rheumatol 46:1478–84
doi: 10.3899/jrheum.180773
Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361(17):1676–1687
doi: 10.1056/NEJMra0902814
Farkas P, Csuka D, Mikes B, Sinkovits G, Reti M, Nemeth E et al (2017) Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies. Immunobiology 222(2):119–127
doi: 10.1016/j.imbio.2016.10.014
Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder MN et al (2017) Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood 130(10):1259–1266
doi: 10.1182/blood-2017-05-782870
Jodele S (2018) Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies. Semin Hematol 55(3):159–166
doi: 10.1053/j.seminhematol.2018.04.003
Teoh CW, Riedl M, Licht C (2016) The alternative pathway of complement and the thrombotic microangiopathies. J World Apheresis Assoc 54(2):220–231
Timmermans S, Abdul-Hamid MA, Vanderlocht J, Damoiseaux J, Reutelingsperger CP, van Paassen P (2017) Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 91(6):1420–1425
doi: 10.1016/j.kint.2016.12.009
Asif A, Nayer A, Haas CS (2017) Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 30(3):347–362
doi: 10.1007/s40620-016-0357-7
de Holanda MI, Porto LC, Wagner T, Christiani LF, Palma LMP (2017) Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol 36(12):2859–2867
doi: 10.1007/s10067-017-3823-2
Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P et al (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89(3):701–711
doi: 10.1016/j.kint.2015.11.026
Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y et al (2016) Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20(2):265–272
doi: 10.1007/s10157-015-1142-y
Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ et al (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87(5):1061–1073
doi: 10.1038/ki.2014.423